Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.

ABSTRACT:

Background/objectives

Interplay between the Hedgehog (HH) and epidermal growth factor receptor (EGFR) pathways modulating the outcome of their signaling activity have been reported in various cancers including pancreatic ductal adenocarcinoma (PDAC). Therefore, simultaneous targeting of these pathways may be clinically beneficial. This Phase I study combined HH and EGFR inhibition in metastatic PDAC patients.

Methods

Combined effects of HH and EGFR inhibition using Vismodegib and Erlotinib with or without gemcitabine in metastatic solid tumors were assessed by CT. Another cohort of patients with metastatic PDAC was evaluated by FDG-PET and tumor biopsies-derived biomarkers.

Results

Treatment was well tolerated with the maximum tolerated dose cohort experiencing no gra

SUBMITTER: McCleary-Wheeler AL 

PROVIDER: S-EPMC7195700 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature